Literature DB >> 3729068

Vascular manifestations of systemic lupus erythematosus.

A Ansari, P H Larson, H D Bates.   

Abstract

Systemic lupus erythematosus (SLE) is a well-known acute and/or chronic multisystem disease of complex autoimmune nature, having predilection for cardiovascular system. While its cardiac manifestations have been adequately studied, there is paucity of information on its vascular manifestations. Accordingly, we studied the incidence of vascular manifestations in 50 consecutive SLE patients seen at our institutions and in private practice during the past 12 years. Systemic hypertension (44%) was the most common vascular manifestation followed by vasculitis (30%), Raynaud's phenomenon (26%), telangiectasis (20%), premature coronary atherosclerosis (6%), digital ulceration (6%), thrombophlebitis (6%), pulmonary hypertension (4%) and portal hypertension (4%). Diffuse systemic vasculitis similar to polyarteritis nodosa was rare (2%). Often more than one lesion was found in the same patient. The clinical diagnosis of these vascular manifestations in the context of the primary disease (SLE) usually does not pose any difficulty except when they antedate it. We also studied the pathology and pathogenesis of some of these vascular lesions in both autopsy and biopsy specimens by both light microscopy and immunofluorescent techniques. Our results as well as those of others who also studied these lesions indicate that immune complex deposition and subsequent complement activation play an important role in the pathogenesis of vasculitis, coronary arteritis and premature coronary atherosclerosis. Corticosteroids and vasodilators remain the drugs of choice for the management of the majority of the symptoms arising from the vascular lesions of SLE.

Entities:  

Mesh:

Year:  1986        PMID: 3729068     DOI: 10.1177/000331978603700601

Source DB:  PubMed          Journal:  Angiology        ISSN: 0003-3197            Impact factor:   3.619


  8 in total

Review 1.  Immune mediated diseases and immune modulation in the neurocritical care unit.

Authors:  Gloria von Geldern; Thomas McPharlin; Kyra Becker
Journal:  Neurotherapeutics       Date:  2012-01       Impact factor: 7.620

2.  Cutaneous vasculitis in systemic lupus erythematosus: association with anti-ribosomal P protein antibody and Raynaud phenomenon.

Authors:  Samuel Katsuyuki Shinjo; Eloísa Bonfá
Journal:  Clin Rheumatol       Date:  2010-03-28       Impact factor: 2.980

3.  Peripheral vascular disease in patients with systemic lupus erythematosus.

Authors:  J McDonald; J Stewart; M B Urowitz; D D Gladman
Journal:  Ann Rheum Dis       Date:  1992-01       Impact factor: 19.103

4.  Risk factors and impact of recurrent lupus nephritis in patients with systemic lupus erythematosus undergoing renal transplantation: data from a single US institution.

Authors:  Paula I Burgos; Elizabeth L Perkins; Guillermo J Pons-Estel; Scott A Kendrick; Jigna M Liu; William T Kendrick; William J Cook; Bruce A Julian; Graciela S Alarcón; Clifton E Kew
Journal:  Arthritis Rheum       Date:  2009-09

5.  High prevalence of asymptomatically poor muscle perfusion of lower extremities measured in systemic lupus erythematosus patients with abnormal myocardial perfusion.

Authors:  C C Lin; H J Ding; Y W Chen; J J Wang; S T Ho; A Kao
Journal:  Rheumatol Int       Date:  2003-07-15       Impact factor: 2.631

6.  Peripheral vascular damage in systemic lupus erythematosus: data from LUMINA, a large multi-ethnic U.S. cohort (LXIX).

Authors:  P I Burgos; L M Vilá; J D Reveille; G S Alarcón
Journal:  Lupus       Date:  2009-10-22       Impact factor: 2.911

7.  Usefulness of thallium-201 muscle scan to investigate perfusion reserve in the lower limbs of patients with systemic lupus erythematusus.

Authors:  H B Hsu; S S Sun; J J H Chen; J J P Tsai; C H Kao; S P ChangLai
Journal:  Rheumatol Int       Date:  2003-08-14       Impact factor: 2.631

8.  Aortic Atherosclerosis in Systemic Lupus Erythematosus.

Authors:  Paola C Roldan; Michelle Ratliff; Richard Snider; Leonardo Macias; Rodrigo Rodriguez; Wilmer Sibbitt; Carlos A Roldan
Journal:  Rheumatology (Sunnyvale)       Date:  2014
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.